A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis

Clinical Therapeutics

Volumn 25, Issue 7, 2003, Pages 2088-2101

  Raghunath, Anan S ^a   Green, Jonathan R B ^b   Edwards, Steven J ^c  

^a St Andrews Group Practice   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Erosive esophagitis; Esomeprazole; Lansoprazole; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG TOLERABILITY; ECONOMIC ASPECT; EMBASE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEALTH ECONOMICS; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0042703254     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80207-2     Document Type: Review

References (32)

1. Galmiche JP, Letessier E, Scarpignato C. Treatment of gastro-oesophageal reflux disease in adults. BMJ. 1998;316:1720-1723.
2. Prescription cost analysis: England 2000. National Health Service, Department of Health; 2001. Available at: http://www.doh.gov.uk/stats/pca2000.htm.
3. Prescription cost analysis: Wales 2000. National Health Service Wales; 2002. Available at: http://www.Wales.nhs.uk/page.cfm?orgid=1&pid=975.
4. National Institute for Clinical Excellence. Technology Appraisal Guidance No. 7: Guidance on the Use of Proton Pump Inhibitors in the Treatment of Dyspepsia. National Institute for Clinical Excellence; July 2000. Available at http://www.nice.org.uk/cat.asp?c=3109.
5. Scriptcount. London: Taylor Nelson Sofres Healthcare: January 2002.
6. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: What it is and what it isn't. BMJ. 1996;312:71-72.
7. Bell NJ, Hunt RH. Progress with proton pump inhibition. Yale J Biol Med. 1992;65:649-657.
8. Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med. 1999;72:181-194.
9. Thomson AB, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut. 2000;47(Suppl 3):A63. Abstract.
10. Rohss K, Claar-Nilsson C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology. 2000;118(Suppl 2):A20. Abstract.
11. Baxter G, Eriksson K, Nilsson LG. Lansoprazole 15 mg provides as effective acid control as esomeprazole 20 mg. Stand J Gastroenterol. 2001;36(Suppl 233):50. Abstract.
12. Wilder-Smith C, Röhss K, Claar-Nilsson C, et al. Esomeprazole 20 mg provides more effective acid control than lansoprazole 15 mg. Gut. 2000;47(Suppl 3):A62-A63. Abstract.
13. Eriksson K, Baxter G, Nilsson LG. Speed of onset of intragastric acid control. Lansoprazole and esomeprazole compared. Stand J Gastroenterol. 2001;36(Suppl 233):49. Abstract.
14. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001;15:1729-1736.
15. Chiba N, de Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology. 1997;112:1798-1810.
16. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001;15:227-231.
17. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials. Clin Ther. 2001;23:998-1017.
18. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583.
19. Howden CW, Ballard ED II, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest. 2002;22:99-109.
20. Edwards S. Meta-analysis of esomeprazole 40 mg and lansoprazole 30 mg in the healing of reflux oesophagitis. Value Health. 2002;5:503. Abstract.
21. Pollock K, Grime J. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): Patient self-regulation of treatment may be an under-exploited resource. Soc Sci Med. 2000;51:1827-1839.
22. Lauritsen K, Devière J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther. 2003;17:333-341.
23. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Outcomes Res. 2002;6:1-14.
24. Plumb JM, Edwards SJ. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis. J Med Econ. 2002;5:25-38.
25. Plumb JM, Edwards SJ. Cost-effectiveness analysis of proton pump inhibitor strategies in the maintenance of healed reflux oesophagitis. Gut. 2003;52(Suppl 1):A44. Abstract.
26. Wilkin D. Primary care budget holding in the United Kingdom National Health Service: Learning from a decade of health service reform. Med J Aust. 2002;176:539-542.
27. Wienbeck M, Barnett J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl. 1989;156:7-13.
28. de Caestecker J. ABC of the upper gastrointestinal tract. Oesophagus: Heartburn. BMJ. 2001;323:736-739.
29. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ. 1998;317:452-456.
30. Zoton [package insert]. Maidenhead, UK: Wyeth UK; 2001.
31. Prescription Cost Analysis: England 2001. National Health Service, Department of Health; 2002. Available at: http://www.doh.gov.uk/stats/pca2001.htm.
32. Nexium [package insert]. Luton, UK: AstraZeneca UK Ltd; 2002.